Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-01-20
DOI
10.3389/fimmu.2020.595818
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma
- (2020) Dirk L. Kienle et al. EXPERT OPINION ON PHARMACOTHERAPY
- T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
- (2020) Philipp M. Roessner et al. LEUKEMIA
- Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents
- (2020) Lenka Sedlarikova et al. Frontiers in Oncology
- Idelalisib rescues natural killer cells from monocyte-induced immunosuppression by inhibiting NOX2-derived reactive oxygen species
- (2020) Ali A Alkhiani et al. Cancer Immunology Research
- Rejection of adoptively transferred Eµ-TCL1 chronic lymphocytic leukemia cells in C57BL/6 substrains or knockout mouse lines
- (2019) Selcen Öztürk et al. LEUKEMIA
- Calcium signal dynamics in T lymphocytes: Comparing in vivo and in vitro measurements
- (2019) Kim S. Friedmann et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types
- (2019) Gianni Monaco et al. Cell Reports
- The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
- (2019) Stalin Chellappa et al. JOURNAL OF IMMUNOLOGY
- Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients
- (2019) Sophia Stock et al. INTERNATIONAL JOURNAL OF CANCER
- IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia
- (2019) Annika Scheffold et al. BLOOD
- Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
- (2019) Jeff P. Sharman et al. JOURNAL OF CLINICAL ONCOLOGY
- PI3K-p110δ contributes to antibody responses by macrophages in chronic lymphocytic leukemia
- (2019) Yu-Chen Enya Chen et al. LEUKEMIA
- Management of toxicity to isoform α-specific PI3K inhibitors
- (2019) S E Nunnery et al. ANNALS OF ONCOLOGY
- Phosphorylation of the multi functional signal transducer B-cell adaptor protein (BCAP) promotes recruitment of multiple SH2/SH3 proteins including GRB2
- (2019) Johannes U. Lauenstein et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia
- (2018) Silvia Martinelli et al. HAEMATOLOGICA
- HGF derived from cancer‑associated fibroblasts promotes vascularization in gastric cancer via PI3K/AKT and ERK1/2 signaling
- (2018) Xusheng Ding et al. ONCOLOGY REPORTS
- Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages
- (2018) Evangelia Goulielmaki et al. Cell Death & Disease
- Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia
- (2018) Silvia Martinelli et al. HAEMATOLOGICA
- Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues
- (2018) Bola S. Hanna et al. LEUKEMIA
- Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling
- (2018) Muhammad Waqas Usman et al. Cell Death & Disease
- Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression
- (2018) Benjamin J. Schmiedel et al. CELL
- PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression
- (2018) Shuai Dong et al. JOURNAL OF CLINICAL INVESTIGATION
- PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia
- (2018) Bola S. Hanna et al. LEUKEMIA
- PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity
- (2018) Larissa S. Carnevalli et al. Journal for ImmunoTherapy of Cancer
- Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
- (2017) Andrew D Zelenetz et al. LANCET ONCOLOGY
- Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia
- (2017) Bola S. Hanna et al. MOLECULAR IMMUNOLOGY
- Origin and differentiation of human memory CD8 T cells after vaccination
- (2017) Rama S. Akondy et al. NATURE
- Effector CD8 T cells dedifferentiate into long-lived memory cells
- (2017) Ben Youngblood et al. NATURE
- Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma
- (2017) Baoqing Tian et al. Oncotarget
- PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells
- (2017) Jacob S. Bowers et al. Frontiers in Immunology
- Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial
- (2017) Jeffrey A Jones et al. Lancet Haematology
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
- (2016) Joseph A. Fraietta et al. BLOOD
- Therapeutic Benefit of Selective Inhibition of p110 PI3-Kinase in Pancreatic Neuroendocrine Tumors
- (2016) A. Soler et al. CLINICAL CANCER RESEARCH
- Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+T Cell Responses during Acute Viral and Intracellular Bacterial Infections
- (2016) Donald T. Gracias et al. JOURNAL OF IMMUNOLOGY
- Context-Specific Function of S6K2 in Th Cell Differentiation
- (2016) Christine Pai et al. JOURNAL OF IMMUNOLOGY
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- PI3Kγ is a molecular switch that controls immune suppression
- (2016) Megan M. Kaneda et al. NATURE
- The 4E-BP–eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes
- (2016) Lomon So et al. Science Signaling
- Nurse-like cells impact on disease progression in chronic lymphocytic leukemia
- (2016) F Boissard et al. Blood Cancer Journal
- Macrophage PI3K Drives Pancreatic Ductal Adenocarcinoma Progression
- (2016) M. M. Kaneda et al. Cancer Discovery
- Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
- (2016) K. Okkenhaug et al. Cancer Discovery
- Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells
- (2016) Olle Werlenius et al. Oncotarget
- The 4E-BP–eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes
- (2016) Lomon So et al. Science Signaling
- PI3K signalling in inflammation
- (2015) P.T. Hawkins et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts
- (2015) J. Paggetti et al. BLOOD
- Drugging PI3K in cancer: refining targets and therapeutic strategies
- (2015) Timothy A Yap et al. CURRENT OPINION IN PHARMACOLOGY
- p70S6K1in the TORC1 pathway is essential for the differentiation of Th17 Cells, but not Th1, Th2, or Treg cells in mice
- (2015) Carl Y. Sasaki et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- PI3Kδ Regulates the Magnitude of CD8+T Cell Responses after Challenge withListeria monocytogenes
- (2015) Verity Q. Pearce et al. JOURNAL OF IMMUNOLOGY
- Nurse like cells: chronic lymphocytic leukemia associated macrophages
- (2015) Frédéric Boissard et al. LEUKEMIA & LYMPHOMA
- Management of adverse events associated with idelalisib treatment: expert panel opinion
- (2015) Steven E. Coutré et al. LEUKEMIA & LYMPHOMA
- Regulation of mTORC1 by PI3K signaling
- (2015) Christian C. Dibble et al. TRENDS IN CELL BIOLOGY
- IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells
- (2014) S. Dong et al. BLOOD
- Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy
- (2014) F. D. Roit et al. HAEMATOLOGICA
- RAS interaction with PI3K p110α is required for tumor-induced angiogenesis
- (2014) Miguel Manuel Murillo et al. JOURNAL OF CLINICAL INVESTIGATION
- Innate PI3K p110 Regulates Th1/Th17 Development and Microbiota-Dependent Colitis
- (2014) E. C. Steinbach et al. JOURNAL OF IMMUNOLOGY
- Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
- (2014) Khaled Ali et al. NATURE
- Idelalisib—targeting PI3Kδ in patients with B-cell malignancies
- (2014) Jan A. Burger et al. Nature Reviews Clinical Oncology
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- Idelalisib — A PI3Kδ Inhibitor for B-Cell Cancers
- (2014) David A. Fruman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Critical Role of IL-15–PI3K–mTOR Pathway in Natural Killer Cell Effector Functions
- (2014) Neethi Nandagopal et al. Frontiers in Immunology
- Two Birds with One Stone: Dual p110δ and p110γ Inhibition
- (2013) Klaus Okkenhaug CHEMISTRY & BIOLOGY
- Phosphoinositide 3′-Kinase Inhibition in Chronic Lymphocytic Leukemia
- (2013) Matthew S. Davids et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Tumor-induced host immunosuppression: Special focus on CLL
- (2013) Christine E. Cutucache INTERNATIONAL IMMUNOPHARMACOLOGY
- Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis
- (2013) Adriana Soler et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation
- (2013) Linda V Sinclair et al. NATURE IMMUNOLOGY
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- PI3K in cancer–stroma interactions: bad in seed and ugly in soil
- (2013) E Hirsch et al. ONCOGENE
- B cell receptor signaling in chronic lymphocytic leukemia
- (2013) Jan A. Burger et al. TRENDS IN IMMUNOLOGY
- Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia
- (2012) J. R. Brown et al. CLINICAL CANCER RESEARCH
- Targeting the EGFR signaling pathway in cancer therapy
- (2012) Parthasarathy Seshacharyulu et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- MT1-MMP regulates the PI3K {middle dot}Mi-2/NuRD-dependent control of macrophage immune function
- (2012) R. Shimizu-Hirota et al. GENES & DEVELOPMENT
- The p110δ isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock
- (2012) Ezra Aksoy et al. NATURE IMMUNOLOGY
- PI3K-Akt-mTORC1-S6K1/2 Axis Controls Th17 Differentiation by Regulating Gfi1 Expression and Nuclear Translocation of RORγ
- (2012) Yutaka Kurebayashi et al. Cell Reports
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
- (2011) J. Hoellenriegel et al. BLOOD
- Immunotherapy with PI3K Inhibitor and Toll-Like Receptor Agonist Induces IFN- +IL-17+ Polyfunctional T Cells That Mediate Rejection of Murine Tumors
- (2011) N. A. Marshall et al. CANCER RESEARCH
- Dual Inhibition of the PI3K/mTOR Pathway Increases Tumor Radiosensitivity by Normalizing Tumor Vasculature
- (2011) E. Fokas et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Modulation of the Tumor Microvasculature by Phosphoinositide-3 Kinase Inhibition Increases Doxorubicin Delivery In Vivo
- (2011) N. Qayum et al. CLINICAL CANCER RESEARCH
- Protein Kinase B Controls Transcriptional Programs that Direct Cytotoxic T Cell Fate but Is Dispensable for T Cell Metabolism
- (2011) Andrew N. Macintyre et al. IMMUNITY
- Phosphoinositide 3-kinase p110γ in immunity
- (2011) Carlotta Costa et al. IUBMB LIFE
- Class IA Phosphoinositide 3-Kinase and Regulate Neutrophil Oxidase Activation in Response to Aspergillus fumigatus Hyphae
- (2011) K. B. Boyle et al. JOURNAL OF IMMUNOLOGY
- Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia
- (2011) Martina Seiffert et al. LEUKEMIA & LYMPHOMA
- A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
- (2011) Markus K Muellner et al. Nature Chemical Biology
- SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
- (2011) Lili Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Innate or Adaptive Immunity? The Example of Natural Killer Cells
- (2011) E. Vivier et al. SCIENCE
- PI3K Plays a Critical Role in Neutrophil Activation by Immune Complexes
- (2011) S. Kulkarni et al. Science Signaling
- PI3K p110 regulates T-cell cytokine production during primary and secondary immune responses in mice and humans
- (2010) D. R. Soond et al. BLOOD
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- PI3K signalling in lymphocyte migration
- (2010) Aurore Saudemont et al. CELL CYCLE
- Role of PI3K in the generation and survival of B cells
- (2010) Markus Werner et al. IMMUNOLOGICAL REVIEWS
- Activity of any class IA PI3K isoform can sustain cell proliferation and survival
- (2010) L. C. Foukas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
- (2010) R. J. O. Dowling et al. SCIENCE
- The PI3K Isoforms p110 and p110 Are Essential for Pre-B Cell Receptor Signaling and B Cell Development
- (2010) F. Ramadani et al. Science Signaling
- Rituximab: Mechanism of Action
- (2010) George J. Weiner SEMINARS IN HEMATOLOGY
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor
- (2009) Dexin Kong et al. EUROPEAN JOURNAL OF CANCER
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α
- (2008) Eli R. Zunder et al. CANCER CELL
- Deletion of PI3K-p85α gene impairs lineage commitment, terminal maturation, cytokine generation and cytotoxicity of NK cells
- (2008) A Awasthi et al. GENES AND IMMUNITY
- The p110δ of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation
- (2008) Hailong Guo et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Phosphoinositide 3-Kinase p110 Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development
- (2008) E. Ciraolo et al. Science Signaling
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search